Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 148Breast Neoplasms 117Prostatic Neoplasms 62Multiple Myeloma 57Neoplasms 56Lung Neoplasms 50Neoplasm Metastasis 44Parkinson Disease 4, Autosomal Dominant Lewy Body 36Ovarian Neoplasms 36Colorectal Neoplasms 35Leukemia, Lymphocytic, Chronic, B-Cell 33Carcinoma, Renal Cell 27Recurrence 26Leukemia, Myeloid, Acute 26Urinary Bladder Neoplasms 25Carcinoma, Hepatocellular 24Small Cell Lung Carcinoma 23Myasthenia Gravis 22Triple Negative Breast Neoplasms 21Endometrial Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Lymphoma, Large B-Cell, Diffuse 20Lymphoma, Follicular 20Melanoma 19Nasopharyngeal Carcinoma 18Fallopian Tube Neoplasms 18Stomach Neoplasms 17Non-Muscle Invasive Bladder Neoplasms 16Brain Neoplasms 16Pancreatic Neoplasms 15

Interventions

Paracentesis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Malignant Ascites × 90 days × Clear all
NCT06432296 2026-05-11

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 3 Active not recruiting
312 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡